Literature DB >> 25641640

The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH.

João Azevedo-Silva1, Odília Queirós1, Ana Ribeiro1, Fátima Baltazar2, Ko H Young3, Peter L Pedersen4, Ana Preto1, Margarida Casal1.   

Abstract

Although the anti-cancer properties of 3BP (3-bromopyruvate) have been described previously, its selectivity for cancer cells still needs to be explained [Ko et al. (2001) Cancer Lett. 173, 83-91]. In the present study, we characterized the kinetic parameters of radiolabelled [14C] 3BP uptake in three breast cancer cell lines that display different levels of resistance to 3BP: ZR-75-1 < MCF-7 < SK-BR-3. At pH 6.0, the affinity of cancer cells for 3BP transport correlates with their sensitivity, a pattern that does not occur at pH 7.4. In the three cell lines, the uptake of 3BP is dependent on the protonmotive force and is decreased by MCTs (monocarboxylate transporters) inhibitors. In the SK-BR-3 cell line, a sodium-dependent transport also occurs. Butyrate promotes the localization of MCT-1 at the plasma membrane and increases the level of MCT-4 expression, leading to a higher sensitivity for 3BP. In the present study, we demonstrate that this phenotype is accompanied by an increase in affinity for 3BP uptake. Our results confirm the role of MCTs, especially MCT-1, in 3BP uptake and the importance of cluster of differentiation (CD) 147 glycosylation in this process. We find that the affinity for 3BP transport is higher when the extracellular milieu is acidic. This is a typical phenotype of tumour microenvironment and explains the lack of secondary effects of 3BP already described in in vivo studies [Ko et al. (2004) Biochem. Biophys. Res. Commun. 324, 269-275].

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25641640     DOI: 10.1042/BJ20140921

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

1.  Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy.

Authors:  A Preto; M Casal; J Azevedo-Silva; D Tavares-Valente; A Almeida; O Queirós; F Baltazar; Y H Ko; P L Pedersen
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

Review 2.  The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Authors:  J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal
Journal:  J Bioenerg Biomembr       Date:  2016-07-25       Impact factor: 2.945

Review 3.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

5.  Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.

Authors:  Katarzyna Niedźwiecka; Mariusz Dyląg; Daria Augustyniak; Grażyna Majkowska-Skrobek; Magdalena Cal-Bąkowska; Young H Ko; Peter L Pedersen; Andre Goffeau; Stanisław Ułaszewski
Journal:  Oncotarget       Date:  2016-10-04

6.  Characterization of acetate transport in colorectal cancer cells and potential therapeutic implications.

Authors:  Suellen Ferro; João Azevedo-Silva; Margarida Casal; Manuela Côrte-Real; Fatima Baltazar; Ana Preto
Journal:  Oncotarget       Date:  2016-09-21

Review 7.  Metabolic Features of Multiple Myeloma.

Authors:  Chaima El Arfani; Kim De Veirman; Ken Maes; Elke De Bruyne; Eline Menu
Journal:  Int J Mol Sci       Date:  2018-04-14       Impact factor: 5.923

Review 8.  Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment.

Authors:  Tengjiao Fan; Guohui Sun; Xiaodong Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

9.  3-Bromopyruvate as an Alternative Option for the Treatment of Protothecosis.

Authors:  Tomasz Jagielski; Katarzyna Niedźwiecka; Katarzyna Roeske; Mariusz Dyląg
Journal:  Front Pharmacol       Date:  2018-04-19       Impact factor: 5.810

10.  Construction and Evaluation of Folic Acid-Modified 3-Bromopyruvate Cubosomes.

Authors:  Fangyan Hou; Hairong Wang; Yawen Zhang; Na Zhu; Hao Liu; Jianchun Li
Journal:  Med Sci Monit       Date:  2020-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.